Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

Niek F. Casteleijn*, A. Lianne Messchendorp, Kyong T. Bae, Eiji Higashihara, Peter Kappert, Vicente Torres, Esther Meijer, Anna M. Leliveld

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients.

70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5).

In these patients [65.7 % male, age 41 +/- 9 years, mGFR 74 +/- 27 mL/min/1.73 m(2) and TKV 1.92 (1.27-2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p <0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4).

Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.

Original languageEnglish
Pages (from-to)375-382
Number of pages8
JournalClinical and experimental nephrology
Issue number3
Early online date23-Jun-2016
Publication statusPublished - Jun-2017


  • Autosomal dominant polycystic kidney disease
  • Tolvaptan
  • Polyuria
  • Ureter


Dive into the research topics of 'Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients'. Together they form a unique fingerprint.

Cite this